Dofamin (dopamine hydrochloride) concentrate for infusions 40 mg/ml. 5 ml. ampoules №10

Description

Dofamin №10 Composition
active substance: dopamine hydrochloride;

1 ml of concentrate contains dopamine hydrochloride 5 mg or 40 mg;

Dofamin №10 excipients:

sodium metabisulfite (E 223), diluted hydrochloric acid, water for injection.

Dofamin №10 Dosage form.

Concentrate for solution for infusion.

Basic physical and chemical properties: clear, colorless or slightly yellowish liquid.

Pharmacotherapeutic group.

Non-glycosidic cardiotonic drugs. Adrenergic and dopaminergic drugs. ATX code C01C A04.

Pharmacological properties

Pharmacodynamics.

By chemical origin, dopamine is a precursor of norepinephrine biosynthesis and has a specific stimulating effect on dopamine receptors, and in large doses it also stimulates α- and β-adrenergic receptors. Under the influence of Dopamine-Darnitsa, the total peripheral vascular resistance (OPSS) and systolic blood pressure increase, heart contractions increase, and cardiac output increases. The heart rate changes relatively little. Myocardial oxygen demand increases, but due to an increase in coronary blood flow, increased oxygen delivery is provided. Dopamine-Darnitsa reduces the resistance of the renal vessels with an increase in blood flow in them, increases glomerular filtration, sodium excretion. The registered pharmacological effects depend on the concentration of the active substance in the blood. In low doses (0.5–2 mcg / kg per minute) it affects mainly dopamine receptors. Expands mesenteric, cerebral, coronary vessels, reduces renal vascular resistance, increases glomerular filtration, increases urine output and sodium excretion from the body.

In the range of medium doses (2–10 μg / kg per minute), it stimulates β1-adrenergic receptors, which causes a positive inotropic effect, and increases the cardiac output.

At doses of 10 μg / kg per minute and above, it has a greater effect on α1-adrenergic receptors than increases the systemic vascular resistance, narrows the renal vessels, increases blood pressure, and reduces urine output.

After stopping the administration, the effect lasts no more than 5-10 minutes

Pharmacokinetics.

Since dopamine is a natural intermediate in the synthesis of norepinephrine, it is impossible to track its pharmacokinetics in the body in most cases.

After intravenous administration, the half-life (T1 / 2) is up to 5 minutes (on average 2 minutes). Dopamine is metabolized in virtually all tissues. Up to 75% of the administered dose is excreted from the body during the first day by the kidneys in the form of inactive metabolites. Up to 25% of the introduced dopamine by the mechanism of reuptake into the neurovesicles is used for the synthesis of norepinephrine. The onset of action is within 5 minutes after the start of administration, the end is 5–10 minutes after the end of the infusion.

Clinical characteristics.

Indications
Conditions of shock or conditions that threaten the occurrence of shock:

heart failure caused by acute myocardial infarction (cardiogenic shock);
severe infections (infectious toxic shock);
state of shock after operations;
a marked decrease in blood pressure (severe hypotension) of any genesis;
hypersensitivity reactions (anaphylactic shock).

Contraindications
Hypersensitivity to dopamine or to other components of the drug.

Pheochromocytoma, thyrotoxicosis.

Tachyarrhythmia, ventricular fibrillation, as well as conditions accompanied by mechanical resistance to filling the ventricles.

Hypovolemia (before starting treatment, it is necessary to compensate for the deficit in circulating blood volume).

Angle-closure glaucoma.

Hyperplasia of the prostate with urinary retention.

Anesthesia with cyclopropane and halogenated hydrocarbons should be avoided.